News

/News

Melinta launches Baxdela™ antibotic in U.S.

Melinta Therapeutics has announced the U.S. launch of intravenous and oral formulations of Baxdela™ (delafloxacin) for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria. “Today’s launch of Baxdela is a significant milestone for Melinta – one that comes on the heels of a very successful year, cementing our leadership position in the antibiotics space,” stated Dan Wechsler, president & chief executive officer of Melinta. more

By |February 6th, 2018|News|0 Comments

U.S. pharma exces expect deals to pick up

The Trump administration’s tax overhaul should accelerate major acquisitions by drugmakers in 2018 after a slow year for deals in 2017, according to senior executives from some of the largest pharmaceutical manufacturers. The U.S. pharmaceutical industry has been consolidating for years even without tax reform. Large companies like Merck & Co Inc, Bristol-Myers Squibb Co and Johnson & Johnson regularly buy or do licensing deals with small companies to help maintain a continuous pipeline of new medicines. more

By |February 6th, 2018|News|0 Comments

JAX scientist wins grant to study precision medicine

A grant from the National Human Genome Research Institute to Jackson Laboratory (JAX) Assistant Professor Albert Cheng, Ph.D., totaling $3,240,117 over five years, will fund the creation of a molecular “toolkit” to explore the effects of epigenetic modifications — chemical changes to DNA and histone proteins that affect how genes are expressed in normal and disease conditions. According to Cheng, the toolkit will be available to biomedical researchers worldwide, with the goal of accelerating personalized and precision medicine. Cheng is located at the Jackson Laboratory's Farmington facility. more

By |February 6th, 2018|News|0 Comments

UConn startups raise record funding in 2017

UConn reports that startups in its Technology Incubation Program (TIP) attracted a record $60 million in funding to help speed up their growth in 2017. TIP startups' gains in equity, debt, grant, and revenue funding amounted to almost $20 million more than the previous record of $39.9 million for debt and equity funding set in 2016, with most investment coming from out-of-state sources. In 2017, TIP was home to 35 companies – the most in the program's history. more

By |February 6th, 2018|News|0 Comments

Arvinas expands floor space at Science Park

Arvinas is adding 30 jobs and taking on an additional 8,500 square feet at its headquarters and research facility in Science Park in New Haven. Arvinas develops treatments for cancers and other difficult-to-treat diseases. When the company completes its current hiring, its workforce will have expanded from the 45 employees it had at the end of last year to about 75 people. more

By |February 6th, 2018|News|0 Comments

Vicki Veltri to lead CT Office of Health Strategy

Connecticut Governor Dannel P. Malloy yesterday announced that he is appointing Victoria Veltri of Colchester to serve as Executive Director of the state’s Office of Health Strategy, a new state office created through the consolidation of several existing resources. Veltri currently serves as Chief Health Policy Advisor in the Office of Lt. Governor Nancy Wyman. In this position, she coordinates the state’s healthcare reform initiatives and serves as a member of the Board of Directors for Access Health CT, the state’s healthcare exchange, as well as on the board of Connecticut Partners for Health. more

By |February 6th, 2018|News|0 Comments

Biohaven reports progress re ALS drug

Biohaven Pharmaceutical Holding Company announced positive results of its bioequivalence study of BHV-0223. The study was designed to demonstrate pharmacokinetic equivalence of the company’s sublingual drug BHV-0223 compared to the reference listed drug Rilutek (riluzole), which is currently the standard of care treatment for patients with Amyotrophic Lateral Sclerosis. more

By |February 6th, 2018|News|0 Comments

Eight CT bioscience projects get CI funding

Eight bioscience projects with ties to Yale, UConn, and Quinnipiac University will receive up to $30,000 under a state program aimed at bolstering the development of health technology. Connecticut Innovations announced the winners in the latest round of funding under its BioScience Pipeline Program more

By |February 6th, 2018|News|0 Comments

Pfizer in diagnostics deal with Foundation Medicine

Pfizer has struck a broad cancer companion diagnostic deal with Foundation Medicine. The alliance will see Foundation Medicine use pan-cancer test FoundationOne CDx as a companion diagnostic for Pfizer drugs. “The combination of our FDA-approved comprehensive genomic profiling platform and molecular information solutions, coupled with Pfizer’s robust oncology portfolio, enables us to enhance the impact of precision oncology to advance patient care,” Melanie Nallicheri, head of biopharma at Foundation Medicine, said in a statement. more

By |February 6th, 2018|News|0 Comments

UConn startups raise record funding in 2017

UConn reports that startups in its Technology Incubation Program (TIP) attracted a record $60 million in funding to help speed up their growth in 2017. TIP startups' gains in equity, debt, grant, and revenue funding amounted to almost $20 million more than the previous record of $39.9 million for debt and equity funding set in 2016, with most investment coming from out-of-state sources. In 2017, TIP was home to 35 companies – the most in the program's history. more

By |January 25th, 2018|News|0 Comments